From January 1, 2023 to March 31, 2023, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 2,559,700 shares, representing 0.27% for CNY 29.99 million under the buyback announced on June 10, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.34 CNY | -0.64% | -1.52% | +1.48% |
May. 27 | ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets | MT |
May. 07 | China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.48% | 1.61B | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- 603567 Stock
- News Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.